Company: RGBP
Filing Date: 2025-12-05
Form Type: 253G1
Source: 0001493152-25-026350
Chunk: 50

Company: Regen BioPharma Inc
Filing Date: 2025-12-05
Form: 253G1
Chunk 50
---
,526 | ) |     |   |     76.61 | % |
| Income tax provision                                      |     |                            |        - |   |     |         |    0.00 | % |     |        |        - |   |     |         |    0.00 | % |     |         |        - |   |     |   |       n/a |   |
| Net loss                                                  |     | $                          | (702,033 | ) |     |         | -396.19 | % |     | $      | (397,507 | ) |     |         | -224.33 | % |     | $       | (304,526 | ) |     |   |     76.61 | % |

Revenues

Revenues from continuing operations were $177,195 for the nine months ended June 30, 2025 and $177,194 for the same period ended 2024. $94,920 and $94,920 of revenue from related parties recognized during the nine months ended June 30 2025 and 2024 consisted of anniversary expense receivable pursuant to a license granted by the Company to Zander Therapeutics, Inc. $82,275 and $82,275 of revenue recognized during the nine months ended June 30, 2025 and 2024 were recognized pursuant to licenses granted to Oncology Pharma, Inc.

Operating Expenses

Operating Expense were $392,680 for the nine months ended June 30, 2025 and $ 509,013 for the same period ended 2024. The primarily operating expense for 2025 consists of $ 267,816 of Consulting & Professional expenses and $67,500 in rent. In the same period in previous year Consulting and Professional fees expenditure were $295,839 During the period ended 2024 research and development expenses amounted to $120,161 constituting the second largest expense recognized during that period.

Other Income

For the three months ended June 30 2025, the Company reported a net other expense of $(126,526) whereas in the same period ended 2024 the Company reported the net other expense of $(22,154). Net other expense for the quarter ended 2025 was primarily driven by the recognition of a Derivative Loss of $(89,259). For the quarter ended June 30, 2025 the Company also recognized higher interest and amortization expenses as compared to the quarter ended 2024.

<div align='